Infective dermatitis associated with HTLV-1

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

Regulatory Watchboard

10 events

Nov 2026Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Everfront Biotech Co., Ltd. — PHASE2, PHASE3

TrialNOT YET RECRUITING

Sep 2026Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma

Assistance Publique - Hôpitaux de Paris — NA

TrialNOT YET RECRUITING

Jun 2026The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

T-MAXIMUM Pharmaceutical Inc — PHASE2

TrialNOT YET RECRUITING

Jun 2026Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NRG Oncology — PHASE3

TrialNOT YET RECRUITING

Jan 2026

ACYCLOVIR: New indication approved

FDAcompleted

Jan 2026Vorasidenib Maintenance for IDH Mutant Astrocytoma

European Organisation for Research and Treatment of Cancer - EORTC — PHASE3

TrialRECRUITING

Sep 2025Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Nader Sanai — EARLY_PHASE1

TrialACTIVE NOT RECRUITING

Jul 2025Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Mayo Clinic — NA

TrialRECRUITING

Jul 2025Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)

LMU Klinikum

TrialRECRUITING

Jul 2025ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Katy Peters, MD, PhD — PHASE1

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Gamimune N

Bayer Corporation

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Gamimune N

(Immune globulin intravenous, human)Orphan drug

Bayer Corporation

Human Immunoglobulin G [EPC]

12.1 Mechanism of Action BIVIGAM is a replacement therapy in patients with primary humoral immunodeficiency (PI) (e.g. agammaglobulinaemia, hypogammag...

Approved Dec 1993FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Infective dermatitis associated with HTLV-1.
Search all trials →

Search clinical trials for Infective dermatitis associated with HTLV-1 →

Recent News & Research

No recent news articles indexed yet for Infective dermatitis associated with HTLV-1.
Search PubMed for Infective dermatitis associated with HTLV-1 →

Browse all Infective dermatitis associated with HTLV-1 news →

Specialist Network

Top 6 by expertise

Christian Grommes, MD, M.D

Memorial Sloan Kettering Cancer Center

📍 NEW YORK, NY

Score 338 trials

Nader Sanai, MD, M.D

Ivy Brain Tumor Center

📍 PHOENIX, AZ

Score 88 trials

Jasper Gerritsen, MD PhD

Erasmus Medical Center

Score 35 trials

Jing Wu, M.D.

National Cancer Institute (NCI)

Score 36 trials

Maria A Dias

Prof. Edgard Santos Teaching Hospital

Iguaracyra Araujo

Prof. Edgard Santos Teaching Hospital

View all Infective dermatitis associated with HTLV-1 specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles